Inside the KLOW Stack: The Four Peptides

In plain English

The KLOW stack is four peptides in one vial. This page breaks each one down — what it is chemically, what role it is supposed to play in the blend, what studies have actually measured it doing, and how it fits into the pharmacokinetic constraints of a co-formulated vial. Inside the KLOW stack, you will find four distinct molecules with four distinct evidence bases, one of which (GHK-Cu) dominates by mass, and none of which has been tested in combination with the other three.

The 80 mg vial: composition at a glance

The canonical KLOW research vial contains 80 mg total, lyophilized, reconstituted with bacteriostatic water:

GHK-Cu is the mass-dominant component by a wide margin — its share reflects both its molecular weight (moderate) and the apparent clinical relevance of delivering a meaningful copper-tripeptide dose.

No CAS number, UNII or PubChem CID exists for the KLOW blend as a whole. It is a mixture, not a defined substance.

KPV — the anti-inflammatory arm

Identity: Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH (alpha-melanocyte-stimulating hormone, residues 11–13). CAS 67727-97-3. Molecular weight 342.44 Da.

Mechanism: KPV is transported into intestinal epithelial cells via PepT1 (SLC15A1), the intestinal di/tripeptide transporter, with a Km of approximately 160 μM. PepT1 is upregulated in inflamed tissue. Once inside, KPV inhibits NF-kB p65/RelA nuclear import and MAP-kinase ERK/p38 activation, and reduces secretion of TNF-α, IL-6, IL-1β and IL-8 ^[3].

Key result: Nanomolar KPV reduced NF-kB and MAPK inflammatory signaling in human intestinal epithelial cells and Jurkat T cells in vitro, and oral KPV at 100 μM in drinking water reduced severity of DSS- and TNBS-induced colitis in C57BL/6 mice ^[3].

Status in KLOW: The anti-inflammatory arm. Its evidence base is strongest in the gut-mucosa context. No approved human indication. KPV has no controlled human clinical trial on record.

GHK-Cu — the matrix and copper arm

Identity: Glycyl-L-Histidyl-L-Lysine chelated 1:1 to a Cu(II) ion (Copper Tripeptide-1). CAS 89030-95-5. Molecular weight 402.92 Da. First isolated from human plasma by Loren Pickart in 1973; endogenous plasma levels decline with age from approximately 200 ng/mL to approximately 80 ng/mL between ages 20 and 60 ^[4].

Mechanism: Broad transcriptomic modulator — GHK shifts expression of approximately 31.2% of human genes at a 50%-or-greater change threshold at 1–10 nM ^[5], with strongest signals on extracellular-matrix remodeling, ubiquitin-proteasome function, DNA repair and antioxidant defense. Supplies copper for lysyl oxidase (the copper-dependent enzyme that crosslinks collagen and elastin) and stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and decorin ^[4].

Key result: In placebo-controlled clinical topical work, GHK-Cu increased collagen production in 70% of treated women (versus 50% for vitamin C, 40% for retinoic acid) with documented improvements in skin laxity, fine lines and wrinkle depth ^[4].

Status in KLOW: The mass-dominant component at 50 mg — about 62.5% of the vial. Its evidence base is the most clinical, with placebo-controlled human topical data, though in cosmetic rather than injectable contexts.

BPC-157 — the angiogenic repair arm

Identity: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids, MW 1419.53 Da). CAS 137525-51-0. Derived from a partial sequence of a protein identified in human gastric juice; originally developed as PL 14736.

Mechanism: Activates the VEGFR2/PI3K/Akt/eNOS angiogenic cascade, upregulates the growth-hormone receptor in tendon fibroblasts, and modulates the nitric-oxide system in a manner partly resistant to L-NAME.

Key results: Accelerated transected rat Achilles tendon healing across biomechanical, functional, microscopic and macroscopic measures ^[2]; improved tendon-to-bone healing after Achilles detachment ^[9]; improved medial collateral ligament healing ^[10]; enhanced tendon fibroblast outgrowth, survival and migration via FAK-paxillin ^[11].

Pharmacokinetics: Elimination half-life under 30 minutes; IM bioavailability 14–19% (rats) / 45–51% (dogs); rapid breakdown into amino-acid metabolites ^[8]. The short half-life is the primary pharmacokinetic tension within the co-formulated KLOW vial — BPC-157 clears far faster than the blend's other components.

Status in KLOW: The angiogenic / tissue-repair arm. Ten mg in the canonical vial. BPC-157 is the component with the deepest tendon and connective-tissue literature; it is also the component with the most discussed regulatory status (FDA 503A Category 2 bulk substances list; not approved for human use).

TB-500 — the cell-migration arm

Identity: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), a synthetic N-acetylated heptapeptide fragment corresponding to the LKKTET actin-binding motif of the 43-amino-acid native protein thymosin beta-4 (Tbeta4). Molecular weight 889.02 Da.

The distinction: The TB-500 fragment and full-length thymosin beta-4 are not interchangeable. Most foundational efficacy data — including the Malinda 1999 wound result ^[1] — are for native Tbeta4. Activities such as integrin-linked kinase activation and epicardial progenitor mobilization have been established for the native protein but not demonstrated for the fragment.

Mechanism: The LKKTET motif sequesters G-actin (monomeric, globular actin), a step linked to cell migration and re-epithelialization.

Key result (native Tbeta4): Re-epithelialization increased by 42% at 4 days and 61% at 7 days in a rat full-thickness wound model; 10 pg stimulated keratinocyte migration 2–3-fold ^[1].

Status in KLOW: The cell-migration and wound-closure arm. Ten mg in the canonical vial. Additionally, thymosin beta-4 is on the WADA Prohibited List (S2), banned at all times in and out of competition — the TB-500 fragment's status under anti-doping rules follows from its derivation from thymosin beta-4.

The inherent pharmacokinetic mismatch

Combining four peptides with markedly different clearance rates in one vial creates an inherent pharmacokinetic mismatch (the situation where co-formulated compounds have very different absorption and clearance timelines). BPC-157 has an elimination half-life under 30 minutes in the formal 2022 PK study ^[8]. The tripeptides KPV (MW 342.44 Da) and GHK-Cu (MW 402.92 Da) are substantially smaller and clear faster. TB-500, as an uncharacterized fragment, has no published PK data.

A single co-formulated dose of the klow stack therefore cannot maintain all four components at matched tissue exposures simultaneously. The components are not pharmacokinetically synchronized. This does not mean the co-formulation is without interest — it means the blend rationale rests on the components occupying complementary windows rather than a synchronized concentration peak.